Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models


Previous studies have shown that multilamellar vesicles (MLV) or other carriers containing purified human C-reactive protein (CRP) have therapeutic activity in preclinical tumor models. Here we evaluated the therapeutic effects of MLV containing novel synthetic peptides, derived from the structure of CRP, on the extent of (a) established lung metastases of fibrosarcoma T241 in C57B1/6 mice, (b) survival of C57B1/6 mice bearing established liver metastases of colon carcinoma MCA-38, and (c) primary tumor growth of Renca renal carcinoma in Balb/c mice. In all cases, a single synthetic CRP peptide, RS-83277, demonstrated significant antitumor effects comparable to that seen with intact CRP. Two other synthetic CRP peptides, RS-83287 and RS-83147, showed no therapeutic activity and were comparable to control MLV containing only buffer. None of the peptides contained sequences homologous with that of the phagocyte stimulant, tuftsin. Activity of MLV-encapsulated RS-83277 was dose-dependent, and a comparable dose of the soluble peptide, given either alone or following injection of buffer-MLV, was ineffective. These results demonstrate immunotherapeutic potential for a novel synthetic peptide derived from CRP, and endogenous acute-phase protein.

This is a preview of subscription content, log in to check access.


  1. 1.

    Barna BP, Deodhar SD, Gautam S, Yen-Lieberman B, Roberts D (1984) Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein. Cancer Res 44: 305

  2. 2.

    Barna BP, James K, Deodhar SD (1987) Activation of human monocyte tumoricidal activity by C-reactive protein. Cancer Res 47: 3959

  3. 3.

    Barna BP, Thomassen MJ, Wiedemann HP, Ahmad M, Deodhar SD (1988) Modulation of human alveolar macrophage tumoricidal activity by C-reactive protein. J Biol Response Mod 7: 1

  4. 4.

    Buchta R, Fridkin M, Pontet M, Romeo D (1987) Synthetic peptides from C-reactive protein containing tufsin-related sequences. Peptides 7: 961

  5. 5.

    Claus D, Siegel J, Petras K, Osmand A, Gewurz H (1977) Interactions of CRP with the first component of human complement. J Immunol 119: 187

  6. 6.

    Deodhar SD (1988) Liposomes in macrophage activation by C-reactive protein (CRP): potential for cancer therapy. In: Gregoriadis G (ed) Liposomes as drug carriers. Wiley, New York, p 447

  7. 7.

    Deodhar SD, James K, Chiang T, Edinger M, Barna BP (1982) Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res 42: 5084

  8. 8.

    Deodhar S, Orangio G, Chiang T, Fazio V (1986) Experimental model for adjuvant therapy of colorectal cancer-Inhibition of liver metastases and prolongation of survival by human C-reactive protein. Am Assoc Cancer Res 27: 311

  9. 9.

    Eppstein DA, Van der Pas MA, Fraser-Smith EB, Felgner PL, Kurahara CG, Matthews TR, Waters RV, Venuti M, Jones G, Mehta R, Lopez-Berestein G (1986) Liposome-encapsulated muramyl dipeptide analog enhances nonspecific host immunity. Immunotherapy 2: 115

  10. 10.

    Fidler IJ (1980) Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science 208: 1469

  11. 11.

    Fidler IJ (1988) Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv Drug Deliv Res 2: 69

  12. 12.

    Fidler IJ, Sone S, Fogler WE, Barnes ZL (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78: 1680

  13. 13.

    Fiedel BA, Gewurz H (1986) Cleaved forms of C-reactive protein are associated with platelet inhibition. J Immunol 136: 2551

  14. 14.

    Fridkin M, Gottlieb P (1981) Tuftsin Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide. Mol Cell Biochem 41: 73

  15. 15.

    Gautam S, Deodhar S (1989) Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study. J Biol Response Mod 8: 560

  16. 16.

    Gautam S, Barna B, Chiang T, Pettay J, Deodhar S (1987) Use of resealed erythrocytes as a delivery system for C-reactive protein (CRP) to generate macrophage-mediated tumoricidal activity. J Biol Response Mod 6: 346

  17. 17.

    Goldrosen MH, Paolini N Jr, Holyoke ED (1986) Description of a murine model of experimental hepatic metastases. JNCI 77: 823

  18. 18.

    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457

  19. 19.

    Kilpatrick JM, Volanakis JE (1985) Opsonic properties of C-reactive protein. Stimulation by phorbol myristate acetate enables human neutrophils to phagocytize C-reactive protein coated cells. J Immunol 134: 3364

  20. 20.

    Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Brody GP (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer, a preliminary study. J Infect Dis 151: 704

  21. 21.

    Matsushima K, Larsen CG, BuBois GC, Oppenheim JJ (1989) Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169: 1485

  22. 22.

    Morley JJ, Kushner I (1982) Serum C-reactive protein levels in disease. Ann NY Acad Sci 389: 406

  23. 23.

    Mortensen RF, Duskiewicz J (1977) Mediation of CRP dependent phagocytosis through mouse macrophage Fc-receptors. J Immunol 119: 1611

  24. 24.

    Murphy GP, Hrushesky WJ (1973) A murine renal cell carcinoma. J NCI 50: 1013

  25. 25.

    Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ, Krakoff IH (1989) Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7: 1915

  26. 26.

    Pepys MB, Baltz ML (1983) Acute phase proteins with specific reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 34: 141

  27. 27.

    Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar AR (1990) Phase I clinical and pharmacological study of liposome-entrappedcis-bisneodecanoato-trans-R,R-1-2-diaminocyclohexane platinum (II). Cancer Res 50: 4254

  28. 28.

    Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Statist Soc [A] 135: 185

  29. 29.

    Phillips NC, Tsao MS (1989) Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res 49: 936

  30. 30.

    Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 42: 1412

  31. 31.

    Robey FA, Ohura K, Futaki S, Fujii N, Yajima H, Goldman N, Jones KD, Wahl S (1987) Proteolysis of human C-reactive protein produces peptides with potent immunomodulating activity. J Biol Chem 262: 7053

  32. 32.

    Shephard EG, Beer SM, Anderson R, Strachan AF, Nel AE, deBeer FC (1989) Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils. J Immunol 143: 2974

  33. 33.

    Shephard EG, Anderson R, Rosen O, Myer MS, Fridkin M, Strachan AF, deBeer FC (1990) Peptides generated from C-reactive protein by a neutrophil membrane protease: amino acid sequence and effects of peptides on neutrophil oxidative metabolism and chemotaxis. J Immunol 145: 1469

  34. 34.

    Sone S, Fidler IJ (1980) Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol 125: 2454

  35. 35.

    Stewart J, Young J (1984) Solid phase peptide synthesis. Pierce Chemical Company, Rockford, Ill.

  36. 36.

    Thomassen MJ, Meeker DP, Deodhar SD, Wiedemann HP, Barna BP (1992) Activation of human monocytes and alveolar macrophages by a synthetic peptide of C-reactive protein. J Immunother (in press)

  37. 37.

    Thombre PS, Deodhar SD (1984) Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokine. Cancer Immunol Immunother 16: 145

  38. 38.

    Treat J, Greenspan AR, Rahman A (1989) Liposome encapsulated doxorubicin: preliminary results of phase I and phase II trials. In: G Lopez-Berestein, IJ Fidler (eds), Liposomes in the therapy of infectious diseases and cancer. Liss, New York, p 353

  39. 39.

    Wilcoxon F (1945) Individual comparisons by ranking methods. Biometric Bull 1: 80

Download references

Author information

Correspondence to Barbara P. Barna.

Additional information

This work was supported in part by grant CA 49950 from the National Cancer Institute, and grant 43618 from the National American Cancer Society

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barna, B.P., Eppstein, D.A., Thomassen, M.J. et al. Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models. Cancer Immunol Immunother 36, 171–176 (1993). https://doi.org/10.1007/BF01741088

Download citation

Key words

  • Immunotherapy
  • C-reactive protein
  • Liposomes
  • Synthetic peptides
  • Murine tumors